Overview Dividends

(GEHC) GE HealthCare Technologies - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US36266G1076

Imaging, Ultrasound, Monitoring, Contrast, Radiopharmaceuticals

Health Care Equipment
Market Cap in USD: 37,812m

IPO / Inception: 2023-01-04
Return 12m vs S&P 500: -13.1%

EPS (Earnings per Share)

EPS CAGR: -16.19%
EPS Trend: -19.0%

Last SUE: 0.31
Qual. Beats: 0

Revenue

Rev. CAGR: 3.09%
Rev. Trend: 71.7%

Last SUE: 0.73
Qual. Beats: 0

Dividends

Dividend Yield	0.20%
Yield on Cost 5y	0.29%
Yield CAGR 5y	24.72%
Payout Consistency	100.0%
Payout Ratio	3.0%

Risk via 5d forecast
Volatility	27.6%
Value at Risk 5%th	41.5%
Relative Tail Risk	-8.52%

Reward TTM
Sharpe Ratio	0.21
Alpha	-14.93
CAGR/Max DD	0.27

Character TTM
Hurst Exponent	0.391
Beta	1.276
Beta Downside	1.617

Drawdowns 3y
Max DD	37.35%
Mean DD	13.30%
Median DD	12.87%

Description: GEHC GE HealthCare Technologies December 17, 2025

GE HealthCare Technologies Inc. (NASDAQ: GEHC) develops, manufactures, and markets medical imaging, advanced visualization, patient-care, and pharmaceutical-diagnostic products and digital solutions across the U.S., Canada, and global markets. The business is organized into four segments: Imaging (CT, MR, X-ray, molecular imaging, womens health), Advanced Visualization Solutions (ultrasound, interventional and surgical guidance), Patient Care Solutions (monitoring, cardiology, consumables, anesthesia, maternal-infant care), and Pharmaceutical Diagnostics (contrast media and radiopharmaceuticals). The company, renamed from GE Healthcare Holding LLC in December 2022, is headquartered in Chicago.

Key recent data points: FY 2023 revenue was ≈ $19.2 billion, with the Imaging segment contributing roughly 55 % of total sales; operating margin stood at 12 % and free cash flow at $2.5 billion. Growth is being driven by AI-enabled imaging workflows, expanding outpatient imaging volumes, and an aging population that fuels demand for diagnostic services. However, margin pressure from supply-chain constraints and evolving reimbursement policies remains a material risk.

For a deeper quantitative dive, consider reviewing GE HC’s detailed financials and valuation metrics on ValueRay.

Piotroski VR‑10 (Strict, 0-10) 4.0

Net Income (2.22b TTM) > 0 and > 6% of Revenue (6% = 1.21b TTM)

FCFTA 0.04 (>2.0%) and ΔFCFTA -1.13pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 8.99% (prev 8.22%; Δ 0.77pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.05 (>3.0%) and CFO 1.85b <= Net Income 2.22b (YES >=105%, WARN >=100%)

Net Debt (6.74b) to EBITDA (3.80b) ratio: 1.77 <= 3.0 (WARN <= 3.5)

Current Ratio 1.18 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (457.0m) change vs 12m ago -0.44% (target <= -2.0% for YES)

Gross Margin 40.80% (prev 41.33%; Δ -0.53pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 57.86% (prev 57.77%; Δ 0.09pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 7.24 (EBITDA TTM 3.80b / Interest Expense TTM 446.0m) >= 6 (WARN >= 3)

Altman Z'' 1.52

(A) 0.05 = (Total Current Assets 11.89b - Total Current Liabilities 10.07b) / Total Assets 36.13b

(B) 0.13 = Retained Earnings (Balance) 4.71b / Total Assets 36.13b

(D) 0.14 = Book Value of Equity 3.56b / Total Liabilities 25.91b

Total Rating: 1.52 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 65.87

1. Piotroski 4.0pt

2. FCF Yield 3.14%

3. FCF Margin 6.92%

4. Debt/Equity 1.08

5. Debt/Ebitda 1.77

6. ROIC - WACC (= 3.81)%

7. RoE 23.74%

8. Rev. Trend 71.74%

9. EPS Trend -19.01%

What is the price of GEHC shares?

As of January 09, 2026, the stock is trading at USD 85.76 with a total of 2,450,185 shares traded.
Over the past week, the price has changed by +4.56%, over one month by +3.21%, over three months by +15.18% and over the past year by +3.06%.

Is GEHC a buy, sell or hold?

GE HealthCare Technologies has received a consensus analysts rating of 4.33. Therefore, it is recommended to buy GEHC.

Strong Buy: 12
Buy: 4
Hold: 5
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the GEHC price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	90.3	5.3%
Analysts Target Price	90.3	5.3%
ValueRay Target Price	86.7	1.1%

GEHC Fundamental Data Overview January 05, 2026

Market Cap USD = 37.81b (37.81b USD * 1.0 USD.USD)
P/E Trailing = 17.147
P/E Forward = 17.4825
P/S = 1.8677
P/B = 3.7753
P/EG = 2.4801
Beta = 1.244
Revenue TTM = 20.25b USD
EBIT TTM = 3.23b USD
EBITDA TTM = 3.80b USD
Long Term Debt = 8.28b USD (from longTermDebt, last quarter)
Short Term Debt = 2.14b USD (from shortTermDebt, last quarter)
Debt = 10.74b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 6.74b USD (from netDebt column, last quarter)
Enterprise Value = 44.55b USD (37.81b + Debt 10.74b - CCE 4.00b)
Interest Coverage Ratio = 7.24 (Ebit TTM 3.23b / Interest Expense TTM 446.0m)
FCF Yield = 3.14% (FCF TTM 1.40b / Enterprise Value 44.55b)
FCF Margin = 6.92% (FCF TTM 1.40b / Revenue TTM 20.25b)
Net Margin = 10.95% (Net Income TTM 2.22b / Revenue TTM 20.25b)
Gross Margin = 40.80% ((Revenue TTM 20.25b - Cost of Revenue TTM 11.98b) / Revenue TTM)
Gross Margin QoQ = 38.69% (prev 39.61%)
Tobins Q-Ratio = 1.23 (Enterprise Value 44.55b / Total Assets 36.13b)
Interest Expense / Debt = 1.03% (Interest Expense 111.0m / Debt 10.74b)
Taxrate = 27.84% (179.0m / 643.0m)
NOPAT = 2.33b (EBIT 3.23b * (1 - 27.84%))
Current Ratio = 1.18 (Total Current Assets 11.89b / Total Current Liabilities 10.07b)
Debt / Equity = 1.08 (Debt 10.74b / totalStockholderEquity, last quarter 9.99b)
Debt / EBITDA = 1.77 (Net Debt 6.74b / EBITDA 3.80b)
Debt / FCF = 4.81 (Net Debt 6.74b / FCF TTM 1.40b)
Total Stockholder Equity = 9.34b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.13% (Net Income 2.22b / Total Assets 36.13b)
RoE = 23.74% (Net Income TTM 2.22b / Total Stockholder Equity 9.34b)
RoCE = 18.33% (EBIT 3.23b / Capital Employed (Equity 9.34b + L.T.Debt 8.28b))
RoIC = 12.32% (NOPAT 2.33b / Invested Capital 18.90b)
WACC = 8.51% (E(37.81b)/V(48.56b) * Re(10.72%) + D(10.74b)/V(48.56b) * Rd(1.03%) * (1-Tc(0.28)))
Discount Rate = 10.72% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.11%
[DCF Debug] Terminal Value 68.55% ; FCFE base≈1.52b ; Y1≈1.47b ; Y5≈1.47b
Fair Price DCF = 37.83 (DCF Value 17.23b / Shares Outstanding 455.5m; 5y FCF grow -4.08% → 3.0% )
EPS Correlation: -19.01 | EPS CAGR: -16.19% | SUE: 0.31 | # QB: 0
Revenue Correlation: 71.74 | Revenue CAGR: 3.09% | SUE: 0.73 | # QB: 0
EPS next Quarter (2026-03-31): EPS=1.00 | Chg30d=-0.008 | Revisions Net=-2 | Analysts=12
EPS next Year (2026-12-31): EPS=4.93 | Chg30d=-0.004 | Revisions Net=-2 | Growth EPS=+8.3% | Growth Revenue=+4.4%

Additional Sources for GEHC Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle